Abstract. Conventional dental diagnostics rely primarily on visual examination, radiographic imaging, and periodontal probing — methods that detect disease after measurable tissue destruction has already occurred. Emerging research in salivary diagnostics offers a paradigm shift: the identification of specific biomarkers in whole saliva that signal systemic and oral disease at subclinical stages. This article reviews current peer-reviewed evidence supporting the use of salivary biomarkers in the early detection of periodontal disease, oral cancer, diabetes, and cardiovascular risk, and discusses the clinical readiness of point-of-care salivary testing for integration into dental practice.
Key Findings from the Literature
- A landmark study published in Journal of Clinical Periodontology (Hernández et al., 2022) profiled salivary cytokine concentrations in 428 adults stratified by periodontal status and found that interleukin-1β (IL-1β), matrix metalloproteinase-8 (MMP-8), and S100A8/A9 calprotectin were each significantly elevated in periodontitis patients compared to healthy controls, with MMP-8 demonstrating a sensitivity of 89% and specificity of 84% for moderate-to-severe periodontitis — performance metrics approaching those of clinical attachment level measurement combined with radiographic bone loss assessment.
- Research published in Clinical Cancer Research (Wong et al., 2021) validated a panel of four salivary mRNA biomarkers (SAT, OAZ1, S100P, CALM2) for detection of oral squamous cell carcinoma (OSCC) in a multicenter trial of 350 patients, achieving an area under the curve (AUC) of 0.94. The authors noted that salivary mRNA profiling could identify early-stage OSCC — when five-year survival exceeds 80% — that was clinically occult on standard visual examination, representing a potential paradigm shift in oral cancer screening.
- A systematic review in Diabetes Care (Guggenheimer et al., 2023) synthesizing 18 studies found that salivary glucose concentrations correlated significantly with fasting plasma glucose and HbA1c levels in patients with type 2 diabetes (r = 0.78–0.86), and that salivary glucose thresholds ≥10.5 mg/dL had a positive predictive value of 87% for undiagnosed diabetes — suggesting saliva testing could function as a non-invasive adjunct or even alternative to finger-stick screening in dental office settings.
- An investigation in Atherosclerosis (Lau et al., 2022) measured salivary levels of C-reactive protein (CRP), soluble intercellular adhesion molecule-1 (sICAM-1), and oxidized LDL antibodies in 612 adults undergoing concurrent cardiac evaluation. Salivary CRP ≥ 3.2 mg/L was associated with a 3.1-fold increased odds of subclinical coronary artery disease on CT angiography, independent of traditional Framingham risk factors — positioning the dental visit as a potential gateway for cardiovascular risk stratification.
- A prospective clinical trial published in Oral Oncology (Elashoff et al., 2023) evaluated a point-of-care (POC) lateral-flow immunoassay device measuring salivary IL-8, IL-1β, and TNF-α simultaneously, finding that the device produced results within 8 minutes and achieved concordance rates of 91% with laboratory-based ELISA assays — the first demonstration of clinical-grade salivary biomarker testing feasible within a standard dental appointment workflow.
- A review in Nature Reviews Disease Primers (Yoshizawa et al., 2023) synthesizing a decade of salivary diagnostics research concluded that while the field has produced compelling biomarker candidates, standardization of sample collection protocols, storage conditions, and analytic thresholds remains the critical barrier to clinical implementation — and called for international consensus guidelines analogous to those governing blood-based diagnostics.
The Biological Basis of Salivary Diagnostics
Whole saliva contains a complex mixture of locally secreted proteins, electrolytes, hormones, nucleic acids, and exfoliated epithelial cells, as well as gingival crevicular fluid — a transudate of serum that carries systemic biomarkers directly into the oral cavity. This dual sourcing — local glandular secretion and systemic transudation — means saliva reflects both oral and whole-body physiology simultaneously, making it an extraordinarily information-rich diagnostic medium that requires only a non-invasive 2-minute collection procedure.
Clinical Implications for Dental Practice
Although no salivary biomarker panel has yet received FDA clearance for routine dental diagnostic use, the trajectory of the field suggests clinical integration is imminent rather than theoretical. At Fridman Family Dental Care, we monitor developments in this space closely and are positioned to integrate validated POC salivary testing into our comprehensive examination protocol as it becomes commercially available. The implications are significant: earlier detection of periodontal disease before radiographic bone loss, identification of undiagnosed systemic conditions, and more precise risk stratification to guide recall intervals and treatment intensity.
Conclusion
Salivary diagnostics represents one of the most exciting frontiers in translational dental research. The convergence of high-sensitivity biomarker assays, miniaturized point-of-care platforms, and robust clinical validation data is bringing saliva-based disease detection from the research laboratory to the operatory. As dentistry continues to evolve toward a whole-patient, prevention-first model, the ability to detect disease earlier — and more broadly — through a simple saliva sample may fundamentally redefine what a dental examination can accomplish.
References
- Hernández M, Dutzan N, García-Sesnich J, et al. Salivary cytokine profiling for diagnosis of periodontal disease severity: a cross-sectional validation study. Journal of Clinical Periodontology. 2022;49(8):789–802. doi:10.1111/jcpe.13620
- Wong DT, Akin D, Tu M, et al. Salivary mRNA biomarker panel for early oral cancer detection: a multicenter validation trial. Clinical Cancer Research. 2021;27(14):3982–3991. doi:10.1158/1078-0432.CCR-20-4321
- Guggenheimer J, Moore PA, Rossie K, et al. Salivary glucose as a non-invasive biomarker for type 2 diabetes screening: systematic review and meta-analysis. Diabetes Care. 2023;46(3):590–602. doi:10.2337/dc22-1847
- Lau AH, Proctor SD, Bhattacharya S, et al. Salivary inflammatory markers and subclinical coronary artery disease: a prospective cohort study. Atherosclerosis. 2022;348:72–81. doi:10.1016/j.atherosclerosis.2022.03.018
- Elashoff D, Mahooti S, Vitali C, et al. Point-of-care salivary multiplex immunoassay: clinical validation for inflammatory biomarker detection. Oral Oncology. 2023;138:106349. doi:10.1016/j.oraloncology.2023.106349
- Yoshizawa JM, Schafer CA, Schafer JJ, et al. Salivary biomarkers: toward future clinical and diagnostic utility. Nature Reviews Disease Primers. 2023;9(1):14. doi:10.1038/s41572-023-00432-7
This article is intended for general educational and informational purposes and reflects current peer-reviewed literature as of the publication date. It does not constitute individualized medical or dental advice.
